

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P3121R1C1

Serial No.

10/700,992

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Goddard et al.

Filing Date

03 Nov 2003

Group

1646

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
ECK ↓	124	2003/0022827 A1	30.01.03	Weiss et al.			25.09.01
	125	2003/0170839 A1	11.09.03	Fouser et al.			14.01.02
	126	2003/0219862 A1	27.11.03	Agarwal et al.			22.06.01
	127	2004/0071699 A1	15.04.04	Renauld et al.			31.07.01
	128	2004/0180399 A1	16.09.04	Renauld et al.			11.03.03
	129	2005/0065321	24.03.05	Presnell et al.			19.10.04
	130	2005/0124796 A1	09.06.05	Presnell et al.			28.01.05
	131	2005/0137129 A1	23.06.05	Agarwal et al.			15.10.03
	132	2005/0214314 A1	29.09.05	Presnell et al.			05.11.04
	133	6,875,845	05.04.05	Presnell et al.			
	134	6,897,292	24.05.05	Presnell et al.			

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

ECK	135	Dumoutier et al., "Cloning and Characterization of IL-22 Binding Protein, a Natural Antagonist of IL-10-Related T Cell-Derived Inducible Factor/IL-22" <u>Journal of Immunology</u> 166:7090-7095 (2001)
	136	Gruenberg et al., "A novel, soluble homologue of the human IL-10 receptor with preferential expression in placenta" <u>Genes and Immunity</u> 2:329-334 (2001)
	*137	Kotenko et al., "Identification, Cloning, and Characterization of a Novel Soluble Receptor That Binds IL-22 and Neutralizes Its Activity <sup>1,2</sup> " <u>J. Immunol.</u> 166:7096-7103 (2001)
	138	NCBI Sequence Database Accession No. AAA91780 (submitted or updated 09-MAR-1996) pps. 1-2
	139	Renauld, Jean-Christophe, "Class II Cytokine Receptors and Their Ligands: Key Antiviral and Inflammatory Modulators" <u>Nature Reviews/Immunology</u> 3:667-676 (Aug 2003)
	140	Su et al., "The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice" <u>Proc. Natl. Acad. Sci USA</u> 95:14400-14405 (1998)
	141	Xu et al., "A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist" <u>Proc. Natl. Acad. Sci. USA</u> 98:9511-9516 (Aug 14, 2001)

Examiner

/Elizabeth C. Kemmerer/

Date Considered

12/14/2006

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P3121R1C1

Serial No.

10/700,992

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Goddard et al.

Filing Date

03 Nov 2003

Group

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
ECK ↓	* 1	4,179,337	18.12.79	Davis et al.			
	* 2	4,275,149	23.06.81	Litman et al.			
	* 3	4,301,144	17.11.81	Iwashita et al.			
	* 4	4,496,689	29.01.85	Mitra, G.			
	* 5	4,640,835	03.02.87	Shimizu et al.			
	* 6	4,657,760	14.05.87	Kung et al.			
	* 7	4,670,417	02.06.87	Iwasaki et al.			
	* 8	4,676,980	30.06.87	Segal et al.			
	* 9	4,736,866	12.04.88	Leder et al.			
	* 10	4,791,192	13.12.88	Nakagawa et al.			
	* 11	4,816,567	28.03.89	Cabilly et al.			
	* 12	4,870,009	26.09.89	Evans et al.			
	* 13	5,206,344	27.04.93	Katre et al.			
	* 14	5,225,212	06.07.94	Martin et al.			
	* 15	5,364,934	15.11.94	Drayna et al.			
	* 16	5,536,637	16.07.96	Jacobs, K.			
	* 17	5,545,806	13.08.96	Lonberg et al.			
	* 18	5,545,807	13.08.96	Surani et al.			
	* 19	5,569,825	29.10.96	Lonberg et al.			
	* 20	5,625,126	29.04.97	Lonberg et al.			
	* 21	5,633,425	27.05.97	Lonberg et al.			
	* 22	5,654,010	05.08.97	Johnson et al.			
	* 23	5,661,016	26.08.97	Lonberg et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass <sup>2</sup>	Translation Yes No	
ECK ↓	* 24	3089	25.07.79	EP (ENGLISH CLAIMS)				
	* 25	404,097	27.12.90	EP (ENGLISH ABSTRACT ATTACHED)				
	* 26	WO 90/13641	15.11.90	PCT				
	* 27	WO 91/00360	10.01.91	PCT				
	* 28	WO 92/20373	26.11.92	PCT				
	* 29	WO 93/08829	13.05.93	PCT				
	* 30	WO 93/11161	10.06.93	PCT				
	* 31	WO 96/07399	14.03.96	PCT				
	* 32	WO 96/27011	06.09.96	PCT				
	* 33	WO 96/40072	19.12.96	PCT				

Examiner

/Elizabeth C. Kemmerer/

Date Considered

12/14/2006

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P3121R1C1	Serial No. 10/700,992		
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Goddard et al.			
				Filing Date 03 Nov 2003	Group		
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
ECK	*	34 WO 97/03692	06.02.97	PCT			
ECK	*	35 WO 97/33551	18.09.97	PCT			
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
ECK	*	36 Altschul and Gish, "Local Alignment Statistics" <u>Methods in Enzymology</u> 266:460-480 (1996)					
	*	37 Altschul et al., "Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs" <u>Nucleic Acids Research</u> 25(17):3389-3402 (1997)					
	*	38 Anderson, W.F., "Human Gene Therapy." <u>Science</u> 256(5058):808-813 (May 8, 1992)					
	*	39 Beal and Dervan, "Second Structural Motif for Recognition of DNA by Oligonucleotide-Directed Triple-Helix Formation" <u>Science</u> 251:1360-1363 (1991)					
	*	40 BLAST Results A-1 - A-6 (Dayhoff)					
	*	41 BLAST Results B-1 - B-4 (GenBank)					
	*	42 Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes" <u>The Journal of Immunology</u> 147(1):86-95 (1991)					
	*	43 Bradley, "Production and Analysis of Chimaeric Mice" <u>Teratocarcinomas and Embryonic Stem Cells: A Practical Approach</u> , E. J. Robertson, ed., IRL, Oxford, Chapter 5, pps. 113-151 (1987)					
	*	44 Brennan et al., "Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G <sub>1</sub> fragments" <u>Science</u> 229:81-83 (July 1985)					
	*	45 Brodeur et al., "Mouse-Human Myeloma Partners for the Production of Heterohybridomas" <u>Monoclonal Antibody Production Techniques and Applications</u> , New York:Marcel Dekker, Inc. pps. 51-63 (1987)					
	*	46 Caron et al., "Engineered Humanized Dimeric Forms of IgG are More Effective Antibodies." <u>Journal of Experimental Medicine</u> 176(4):1191-1195 (1992)					
	*	47 Carter et al., "Improved Oligonucleotide Site-Directed Mutagenesis Using M13 Vectors" <u>Nucl. Acids Res.</u> 13(12):4431-4443 (June 25, 1986)					
	*	48 Chevray and Nathans, "Protein Interaction Cloning in Yeast: Identification of Mammalian Proteins That React With the Leucine Zipper of Jun" <u>Proc. Natl. Acad. Sci. USA</u> 89:5789-5793 (July 1992)					
	*	49 Chien et al., "The Two-Hybrid System: A Method to Identify and Clone Genes for Proteins that Interact with a Protein of Interest." <u>Proc. Natl. Acad. Sci. USA</u> 88:9578-9582 (1991)					
	*	50 Chothia, "The Nature of the Accessible and Buried Surfaces in Proteins" <u>Journal Mol. Biol.</u> 105:1-12 (1976)					
	*	51 Cleland., "Design and Production of Single Immunization Vaccines Using Polylactide Polyglycolide Microsphere Systems." <u>Vaccine Design: The Subunit and Adjuvant Approach</u> , Powell and Newman, New York:Plenum Press pps. 439-462 (1995)					
	*	52 Cohen, Jack S. ed. <u>Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression</u> , Boca Raton, FL:CRC Press, Inc. (1989)					
Examiner /Elizabeth C. Kemmerer/				Date Considered 12/14/2006			

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P3121R1C1	Serial No. 10/700,992
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Goddard et al.	
				Filing Date 03 Nov 2003	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
ECK	* 53	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <u>Monoclonal Antibodies and Cancer Therapy</u> , New York: Alan R. Liss, Inc. pps. 77-96 (1985)			
	* 54	Coligan et al. <u>Current Protocols in Immunology</u> , Chapter 5, 1(2) (1991)			
	* 55	Cooney et al., "Site-Specific Oligonucleotide Binding Represses Transcription of the Human c-myc Gene in Vitro" <u>Science</u> 241:456-459 (July 22, 1988)			
	* 56	Creighton, Thomas E. <u>Proteins: Structures and Molecular Properties</u> , N.Y.: W.H. Freeman & Co. (1983)			
	* 57	David and Reisfeld., "Protein Iodination with Solid State Lactoperoxidase." <u>Biochemistry</u> 13(5):1014-1021 (1974)			
	* 58	Dzau et al., "Gene Therapy for Cardiovascular Disease." <u>Trends in Biotechnology</u> . 11:205-210 (1993)			
	* 59	Evan et al., "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product" <u>Molecular &amp; Cellular Biology</u> 5:3610-3616 (1985)			
	* 60	Field et al., "Purification of a RAS-Responsive Adenylyl Cyclase Complex from <i>Saccharomyces cerevisiae</i> by Use of an Epitope Addition Method" <u>Molecular &amp; Cellular Biology</u> 8:2159-2165 (1988)			
	* 61	Fields and Song., "A Novel Genetic System to Detect Protein-Protein Interactions." <u>Nature</u> . 340:245-246 (1989)			
	* 62	Fishwild et al., "High-Avidity Human IgGk Monoclonal Antibodies From a Novel Strain of Minilocus Transgenic Mice" <u>Nature Biotechnology</u> . 14(7):845-851 (Jul 1996)			
	* 63	Gruber et al., "Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in <i>Escherichia Coli</i> " <u>Journal of Immunology</u> 152:5368-5374 (1994)			
	* 64	Holliger et al., "'Diabodies': Small Bivalent and Bispecific Antibody Fragments." <u>Proc. Natl. Acad. Sci. USA</u> 90:6444-6448 (Jul 1993)			
	* 65	Holmes et al., "Structure and Functional Expression of a Human Interleukin-8 Receptor" <u>Science</u> 253(5025):1278-1280 (1991)			
	* 66	Hoogenboom and Winter, "By-Passing Immunisation: Human Antibodies from Synthetic Repertoires of Germline V <sub>H</sub> Gene Segments Rearranged in Vitro" <u>J. Mol. Biol.</u> 227:381-388 (1992)			
	* 67	Hopp et al., "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification" <u>Bio/Technology</u> 6:1204-1210 (1988)			
	* 68	Hora et al., "Controlled Release of Interleukin-2 from Biodegradable Microspheres" <u>Bio/Technology</u> 8:755-758 (August 1990)			
	* 69	Johnson et al., "A month-long effect from a single injection of microencapsulated human growth hormone" <u>Nature Medicine</u> 2(7):795-799 (Jul 1996)			
	* 70	Jones et al., "Replacing the Complementarity-Determining Regions in a Human Antibody with Those From a Mouse." <u>Nature</u> . 321:522-525 (May 29, 1986)			
	* 71	Klein et al., "Selection for Genes Encoding Secreted Proteins and Receptors" <u>Proc. Natl. Acad. Sci. USA</u> 93(14):7108-7113 (1996)			
✓	* 72	Kohler and Milstein., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity." <u>Nature</u> . 256:495-497 (August 7, 1975)			
Examiner /Elizabeth C. Kemmerer/			Date Considered 12/14/2006		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P3121R1C1	Serial No. 10/700,992
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Goddard et al.	
				Filing Date 03 Nov 2003	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
ECK	* 73	Kostelny et al., "Formation of a Bispecific Antibody by the Use of Leucine Zippers" <u>Journal of Immunology</u> 148(5):1547-1553 (1992)			
	* 74	Kozbor et al., "A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies" <u>The Journal of Immunology</u> 133(6):3001-3005 (1984)			
	* 75	Lee et al., "Complexes Formed by (Pyrimidine) <sub>n</sub> (purine) <sub>n</sub> DNAs on Lowering the pH are Three-Stranded." <u>Nucl. Acids Res.</u> 6:3073-3091 (1979)			
	* 76	Lewis, "Controlled release of bioactive agents from lactide/glycolide polymers" <u>Biodegradable Polymers as Drug Delivery Systems</u> , M. Chasin and R Langer, New York:Marcel Dekker pps. 1-41 (1990)			
	* 77	Li et al., "Targeted Mutation of the DNA Methyltransferase Gene Results in Embryonic Lethality." <u>Cell</u> . 69:915-926 (Jun 1992)			
	* 78	Lonberg and Huszar., "Human Antibodies From Transgenic Mice" <u>International Reviews of Immunology</u> 13(1):65-93 (1995)			
	* 79	Lonberg et al., "Antigen-Specific Human Antibodies From Mice Comprising Four Distinct Genetic Modifications" <u>Nature</u> . 368(6474):856-859 (Apr 28, 1994)			
	* 80	Lutz-Freyermuth et al., "Quantitative Determination That One of Two Potential RNA-binding Domains of the A Protein Component of the U1 Small Nuclear Ribonucleoprotein Complex Binds with High Affinity to Stem-loop II of U1 RNA" <u>Proc. Natl. Acad. Sci. USA</u> 87:6393-6397 (1990)			
	* 81	Marasco et al., "Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp 120 single-chain antibody" <u>Proc. Natl. Acad. Sci. USA</u> 90:7889-7893 (1993)			
	* 82	Marks et al., "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling" <u>Bio/Technology</u> 10:779-783 (1992)			
	* 83	Marks et al., "By-Passing Immunization: Human Antibodies From V-gene Libraries Displayed On Phage" <u>J. Mol. Biol.</u> 222:581-597 (1991)			
	* 84	Martin et al., "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K <sup>+</sup> Channel Currents" <u>Science</u> 255:192-194 (1992)			
	* 85	Merrifield, R.B., "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide" <u>J. Am. Chem. Soc.</u> 85(14):2149-2154 (Jul 1963)			
	* 86	Milstein and Cuello, "Hybrid Hybridomas and Their Use in Immunohistochemistry" <u>Nature</u> 305:537-540 (Oct 1983)			
	* 87	Mordenti et al., "The Use of Interspecies Scaling in Toxicokinetics" <u>Toxicokinetics and New Drug Development</u> , Yacobi et al., eds., New York:Pergamon Press pps. 42-96 (1989)			
	* 88	Morrison, S., "Immunology: Success in Specification" <u>Nature</u> . 368(6474):812-813 (Apr 28, 1994)			
	* 89	Munson and Rodbard, "LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems" <u>Analytical Biochemistry</u> 107:220-239 (1980)			
	* 90	Neuberger, M., "Generating High-Avidity Human Mabs in Mice" <u>Nature Biotechnology</u> . 14(7):826 (Jul 1996)			
	* 91	Nielsen et al., "Identification of Prokaryotic and Eukaryotic Signal Peptides and Prediction of Their Cleavage Sites" <u>Protein Engineering</u> . 10(1):1-6 (1997)			
✓	* 92	Nygren, H., "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents" <u>The Journal of Histochemistry and Cytochemistry</u> 30(5):407-412 (1982)			
Examiner /Elizabeth C. Kemmerer/				Date Considered 12/14/2006	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P3121R1C1	Serial No. 10/700,992
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Goddard et al.	
				Filing Date 03 Nov 2003	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
ECK	* 93	Okano et al., "Myelin Basic Protein Gene and the Function of Antisense RNA in Its Repression in Myelin-Deficient Mutant Mouse." <u>J. Neurochemistry</u> . 56(2):560-567 (1991)			
	* 94	Paborsky et al., "Mammalian Cell Transient Expression of Tissue Factor for the Production of Antigen" <u>Protein Eng.</u> 3(6):547-553 (1990)			
	* 95	Pain et al., "Preparation of Protein A-Peroxidase Monoconjugate Using a Heterobifunctional Reagent, and its Use in Enzyme Immunoassays" <u>Journal of Immunological Methods</u> 40:219-230 (1981)			
	* 96	Pluckthun., "Antibodies From Escherichia coli." <u>The Pharmacology of Monoclonal Antibodies: Handbook of Experimental Pharmacology</u> , Rosenberg and Moore, eds., Berlin:Springer-Verlag, Chapter 11, Vol. 113:269-315 (1994)			
	* 97	Presta, L., "Antibody Engineering" <u>Curr. Op. Struct. Biol.</u> 2:593-596 (1992)			
	* 98	Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (Mar 24, 1988)			
	* 99	Rossi, J.J., "Making Ribozymes Work in Cells." <u>Current Biology</u> . 4(5):469-471 (1994)			
	*100	Sambrook et al. <u>Molecular Cloning: A Laboratory Manual</u> , Second edition, New York: Cold Spring Harbor Laboratory Press (1989)			
	*101	Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene" <u>Journal of Experimental Medicine</u> 175:217-225 (Jan 1, 1992)			
	*102	Shopes, "A Genetically Engineered Human IgG Mutant With Enhanced Cytolytic Activity." <u>Journal of Immunology</u> . 148(9):2918-2922 (1992)			
	*103	Skinner et al., "Use of the Glu-Glu-Phe C-Terminal Epitope for Rapid Purification of the Catalytic Domain of Normal and Mutant ras GTPase-activating Proteins." <u>J. Bio. Chem.</u> 266:14163-14166 (1991)			
	*104	Stein and Cohen., "Oligodeoxynucleotides as Inhibitors of Gene Expression: A Review." <u>Cancer Research</u> 48:2659-2668 (May 15, 1988)			
	*105	Stevenson et al., "A Chimeric Antibody With Dual Fc Regions (bisFabFc) Prepared by Manipulations at the IgG Hinge." <u>Anti-Cancer Drug Design</u> . 3(4):219-230 (1989)			
	*106	Stewart et al. <u>Solid-Phase Peptide Synthesis</u> , San Francisco, CA:W.H. Freeman Co. (1969)			
	*107	Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" <u>Methods in Enzymology</u> 121:210-228 (1986)			
	*108	Thomas and Capecchi, "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells." <u>Cell</u> . 51:503-512 (Nov 1987)			
	*109	Thomas, P., "Hybridization of Denatured RNA and Small DNA Fragments Transferred to Nitrocellulose" <u>Proc. Natl. Acad. Sci. USA</u> 77(9):5201-5205 (September 1980)			
	*110	Traunecker et al., "Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells" <u>EMBO Journal</u> 10(12):3655-3659 (1991)			
	*111	Tutt et al., "Trispecific F(ab') <sub>3</sub> Derivatives That Use Cooperative Signaling Via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells" <u>J. Immunol.</u> 147(1):60-69 (1991)			
✓	*112	van der Krol et al., "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences." <u>Biotechniques</u> . 6(10):958-976 (1988)			
Examiner /Elizabeth C. Kemmerer/				Date Considered 12/14/2006	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

